These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

751 related items for PubMed ID: 14993498

  • 1. Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution.
    Betjes MG, van Agteren M.
    Nephrol Dial Transplant; 2004 Jun; 19(6):1546-51. PubMed ID: 14993498
    [Abstract] [Full Text] [Related]

  • 2. Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies.
    Dümichen MJ, Seeger K, Lode HN, Kühl JS, Ebell W, Degenhardt P, Singer M, Geffers C, Querfeld U.
    J Hosp Infect; 2012 Apr; 80(4):304-9. PubMed ID: 22342714
    [Abstract] [Full Text] [Related]

  • 3. A new haemodialysis catheter-locking agent reduces infections in haemodialysis patients.
    Taylor C, Cahill J, Gerrish M, Little J.
    J Ren Care; 2008 Sep; 34(3):116-20. PubMed ID: 18786077
    [Abstract] [Full Text] [Related]

  • 4. Taurolidine-citrate-heparin catheter lock solution reduces staphylococcal bacteraemia rates in haemodialysis patients.
    Murray EC, Deighan C, Geddes C, Thomson PC.
    QJM; 2014 Dec; 107(12):995-1000. PubMed ID: 24939191
    [Abstract] [Full Text] [Related]

  • 5. A randomized double-blind controlled trial of taurolidine-citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis.
    Solomon LR, Cheesbrough JS, Ebah L, Al-Sayed T, Heap M, Millband N, Waterhouse D, Mitra S, Curry A, Saxena R, Bhat R, Schulz M, Diggle P.
    Am J Kidney Dis; 2010 Jun; 55(6):1060-8. PubMed ID: 20207458
    [Abstract] [Full Text] [Related]

  • 6. A Taurolidine-Citrate-Heparin Lock Solution Effectively Eradicates Pathogens From the Catheter Biofilm in Hemodialysis Patients.
    Zwiech R, Adelt M, Chrul S.
    Am J Ther; 2016 Jun; 23(2):e363-8. PubMed ID: 23665885
    [Abstract] [Full Text] [Related]

  • 7. Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT).
    Gudiol C, Nicolae S, Royo-Cebrecos C, Aguilar-Guisado M, Montero I, Martín-Gandul C, Perayre M, Berbel D, Encuentra M, Arnan M, Cisneros-Herreros JM, Carratalà J.
    Trials; 2018 May 02; 19(1):264. PubMed ID: 29720244
    [Abstract] [Full Text] [Related]

  • 8. Biofilm formation in long-term central venous catheters in children with cancer: a randomized controlled open-labelled trial of taurolidine versus heparin.
    Handrup MM, Fuursted K, Funch P, Møller JK, Schrøder H.
    APMIS; 2012 Oct 02; 120(10):794-801. PubMed ID: 22958287
    [Abstract] [Full Text] [Related]

  • 9. Taurolidine-based catheter lock regimen significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters.
    Winnicki W, Herkner H, Lorenz M, Handisurya A, Kikić Ž, Bielesz B, Schairer B, Reiter T, Eskandary F, Sunder-Plassmann G, Sengoelge G.
    Kidney Int; 2018 Mar 02; 93(3):753-760. PubMed ID: 28890326
    [Abstract] [Full Text] [Related]

  • 10. Impact of locking solutions on conditioning biofilm formation in tunnelled haemodialysis catheters and inflammatory response activation.
    Jiménez Hernández M, Soriano A, Filella X, Calvo M, Coll E, Rebled JM, Poch E, Graterol F, Compte MT, Maduell F, Fontsere N.
    J Vasc Access; 2021 May 02; 22(3):370-379. PubMed ID: 32691665
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients.
    Koldehoff M, Zakrzewski JL.
    Int J Antimicrob Agents; 2004 Nov 02; 24(5):491-5. PubMed ID: 15519483
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Reduced colonization and infection with miconazole-rifampicin modified central venous catheters: a randomized controlled clinical trial.
    Yücel N, Lefering R, Maegele M, Max M, Rossaint R, Koch A, Schwarz R, Korenkov M, Beuth J, Bach A, Schierholz J, Pulverer G, Neugebauer EA.
    J Antimicrob Chemother; 2004 Dec 02; 54(6):1109-15. PubMed ID: 15537696
    [Abstract] [Full Text] [Related]

  • 16. Taurolidine and Heparin as Catheter Lock Solution for Central Venous Catheters in Hemodialysis.
    Nguyen T, Camins BC, Butler DA.
    Am J Ther; 2004 Dec 02; 31(4):e398-e409. PubMed ID: 38710029
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of taurolidine/urokinase versus taurolidine/heparin as a tunneled catheter lock solution in hemodialysis patients: a prospective, randomized, controlled study.
    Al-Ali F, Hamdy AF, Hamad A, Elsayed M, Zafar Iqbal Z, Elsayed A, Ibrahim R, Tolba H, Buanan H, Fawzy A.
    Nephrol Dial Transplant; 2018 Apr 01; 33(4):619-626. PubMed ID: 29106676
    [Abstract] [Full Text] [Related]

  • 18. Comparison of ML8-X10 (a prototype oil-in-water micro-emulsion based on a novel free fatty acid), taurolidine/citrate/heparin and vancomycin/heparin antimicrobial lock solutions in the eradication of biofilm-producing staphylococci from central venous catheters.
    Luther MK, Mermel LA, LaPlante KL.
    J Antimicrob Chemother; 2014 Dec 01; 69(12):3263-7. PubMed ID: 25096074
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prophylaxis against dialysis catheter-related bacteremia with a novel antimicrobial lock solution.
    Allon M.
    Clin Infect Dis; 2003 Jun 15; 36(12):1539-44. PubMed ID: 12802753
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.